Treatment with an antibody against CD122 reduced CXCR6+ CD8+ PD-1high T cells (Dudek et al., 2021); Lacotte et al. (2023) in their study, confirmed that after deletion of the CXCR6+ CD8+ PD-1high T cells, the anti-CD122 treatment restored the tumor-specific T cell phenotype and prevented tumor growth. This evidence concerns the gene CD8A and neoplasm.